ProPhase Labs to Present at the 2024 ThinkEquity Conference

Rhea-AI Summary

ProPhase Labs (NASDAQ: PRPH), a next generation biotech, genomics, and diagnostics company, has announced its participation in The ThinkEquity Conference on October 30, 2024, at the Mandarin Oriental Hotel in New York. Ted Karkus, CEO and Chairman of the Board of Directors, will present at 1PM ET on October 30th.

The conference is known for featuring numerous company presentations, attracting hundreds of attendees, and facilitating one-on-one meetings between companies and investors. ProPhase's presentation will be live-streamed, and interested investors can register to attend and schedule one-on-one meetings throughout the day.

This event provides ProPhase Labs with a valuable opportunity to connect with potential investors and showcase their latest developments in the biotech, genomics, and diagnostics sectors.

GARDEN CITY, NY, Oct. 22, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (the “Company” or “ProPhase”), a next generation biotech, genomics, and diagnostics company, today announced that it will be participating in The ThinkEquity Conference on October 30, 2024, at the Mandarin Oriental Hotel in New York. Past ThinkEquity conferences have featured over 70 company presentations, 700+ attendees, and 500+ one-on-one meetings, providing a valuable platform for companies and investors to connect.".

Ted Karkus, CEO and Chairman of the Board of Directors, will be presenting at 1PM ET on October 30^th. One-on-one investor meetings will be held throughout the day. Interested investors can register to attend and schedule one-on-one meetings here.

The presentation will also be live-streamed at the following link: https://wsw.com/webcast/tep25/prph/1692576

About ProPhase Labs

ProPhase Labs Inc. (Nasdaq: PRPH) (“ProPhase”) is a next-generation biotech, genomics and diagnostics company. Our goal is to create a healthier world with bold action and the power of insight. We’re revolutionizing healthcare with industry-leading Whole Genome Sequencing solutions, while developing potential game changer diagnostics and therapeutics in the fight against cancer. This includes a potentially life-saving cancer test focused on early detection of esophageal cancer and potential breakthrough cancer therapeutics with novel mechanisms of action. Our world-class CLIA labs and cutting-edge diagnostic technology provide wellness solutions for healthcare providers and consumers. We develop, manufacture, and commercialize health and wellness solutions to enable people to live their best lives. We are committed to executional excellence, smart diversification, and a synergistic, omni-channel approach. ProPhase Labs’ valuable subsidiaries, their synergies, and significant growth underscore our multi-billion-dollar potential.

Media Relations and Institutional Investor Contact:

ProPhase Labs, Inc.
267-880-1111
investorrelations@prophaselabs.com

Retail Investor Relations Contact:

Renmark Financial Communications
John Boidman
514-939-3989
Jboidman@renmarkfinancial.com

Source: ProPhase Labs, Inc.

FAQ

When and where is ProPhase Labs (PRPH) presenting at the ThinkEquity Conference?

ProPhase Labs (PRPH) is presenting at the ThinkEquity Conference on October 30, 2024, at 1PM ET. The conference is being held at the Mandarin Oriental Hotel in New York.

Who will be presenting for ProPhase Labs (PRPH) at the 2024 ThinkEquity Conference?

Ted Karkus, CEO and Chairman of the Board of Directors of ProPhase Labs (PRPH), will be presenting at the 2024 ThinkEquity Conference.

How can investors attend or view ProPhase Labs' (PRPH) presentation at the ThinkEquity Conference?

Investors can register to attend the conference and schedule one-on-one meetings with ProPhase Labs (PRPH). The presentation will also be live-streamed at https://wsw.com/webcast/tep25/prph/1692576.

What type of company is ProPhase Labs (PRPH)?

ProPhase Labs (PRPH) is described as a next generation biotech, genomics, and diagnostics company.